0001209191-14-009875.txt : 20140212 0001209191-14-009875.hdr.sgml : 20140212 20140212182658 ACCESSION NUMBER: 0001209191-14-009875 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140212 FILED AS OF DATE: 20140212 DATE AS OF CHANGE: 20140212 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ARGOS THERAPEUTICS INC CENTRAL INDEX KEY: 0001105533 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 562110007 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4233 TECHNOLOGY DR CITY: DURHAM STATE: NC ZIP: 27704 BUSINESS PHONE: 9192876300 MAIL ADDRESS: STREET 1: 4233 TECHNOLOGY DR CITY: DURHAM STATE: NC ZIP: 27704 FORMER COMPANY: FORMER CONFORMED NAME: MERIX BIOSCIENCE INC DATE OF NAME CHANGE: 20000207 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MIESOWICZ FREDERICK CENTRAL INDEX KEY: 0001022855 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35443 FILM NUMBER: 14602021 MAIL ADDRESS: STREET 1: CELLCOR INC STREET 2: 200 WELLS AVE CITY: NEWTON STATE: MA ZIP: 02159 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2014-02-12 0 0001105533 ARGOS THERAPEUTICS INC ARGS 0001022855 MIESOWICZ FREDERICK C/O ARGOS THERAPEUTICS, INC. 4233 TECHNOLOGY DRIVE DURHAM NC 27704 0 1 0 0 COO Common Stock 2014-02-12 4 C 0 37 A 37 D Common Stock 2014-02-12 4 C 0 619 A 656 D Common Stock 2014-02-12 4 C 0 4941 A 5597 D Series C Preferred Stock 2014-02-12 4 C 0 37 0.00 D Common Stock 37 0 D Series D Preferred Stock 2014-02-12 4 C 0 619 0.00 D Common Stock 619 0 D Series E Preferred Stock 2014-02-12 4 C 0 4941 0.00 D Common Stock 4941 0 D Each share of Series C Preferred Stock converted into 0.0074 shares of common stock upon the closing of the Issuer's initial public offering of common stock for no additional consideration. The Series C Preferred Stock has no expiration date. Each share of Series D Preferred Stock converted into 0.1667 shares of common stock upon the closing of the Issuer's initial public offering of common stock for no additional consideration. The Series D Preferred Stock has no expiration date. Each share of Series E Preferred Stock converted into 0.1667 shares of common stock upon the closing of the Issuer's initial public offering of common stock for no additional consideration. The Series E Preferred Stock has no expiration date. /s/Frederick M. Miesowicz 2014-02-12